Department of Psychotherapy and Systems Neuroscience, Justus Liebig University of Giessen, Giessen, Germany.
Center for Mind, Brain and Behavior (CMBB), Philipps University of Marburg and Justus Liebig University of Giessen, Marburg, Germany.
BMC Psychiatry. 2024 Oct 5;24(1):657. doi: 10.1186/s12888-024-06108-0.
Emotional disorders such as depression and anxiety disorders share substantial similarities in their etiology and treatment. In recent decades, these commonalities have been increasingly recognized in classification systems and treatment programs crossing diagnostic boundaries.
To examine the prospective effects of different transdiagnostic markers on relevant treatment outcomes, we plan to track a minimum of N = 200 patients with emotional disorders during their routine course of cognitive behavioral therapy at two German outpatient clinics. We will collect a wide range of transdiagnostic markers, ranging from basic perceptual processes and self-report measures to complex behavioral and neurobiological indicators, before entering therapy. Symptoms and psychopathological processes will be recorded before entering therapy, between the 20th and 24th therapy session, and at the end of therapy.
Our results could help to identify transdiagnostic markers with high predictive power, but also provide deeper insights into which patient groups with which symptom clusters are less likely to benefit from therapy, and for what reasons.
The trial was preregistered at the German Clinical Trial Register (DRKS-ID: DRKS00031206; 2023-05-09).
抑郁和焦虑障碍等情绪障碍在病因和治疗上有很多相似之处。近几十年来，这些共性在跨诊断界限的分类系统和治疗方案中得到了越来越多的认可。
为了研究不同的跨诊断标记物对相关治疗结果的前瞻性影响，我们计划在德国的两家门诊诊所中，对至少 200 名患有情绪障碍的患者进行跟踪，这些患者在接受认知行为治疗的过程中会接受常规治疗。在进入治疗之前，我们将收集广泛的跨诊断标记物，从基本的感知过程和自我报告测量到复杂的行为和神经生物学指标。在进入治疗之前、第 20 至 24 次治疗期间和治疗结束时，我们将记录症状和心理病理过程。
我们的研究结果可能有助于确定具有高预测能力的跨诊断标记物，还可以深入了解哪些患者群体和哪些症状群不太可能从治疗中受益，以及原因是什么。
该试验已在德国临床试验注册处（DRKS-ID：DRKS00031206；2023-05-09）进行了预先注册。
